Lupin Pharmaceutical Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Lupin Pharmaceutical Inc Pharmaceutical Import Records from India — 3 Products, $2.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lupin Pharmaceutical Inc — Pharmaceutical Importer Profile (2026) | 3 Products, $2.2M Trade | TransData Nexus

Lupin Pharmaceutical Inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $2.2M Total Trade · DGFT Verified

Lupin Pharmaceutical Inc is a pharmaceutical importer based in United States with a total trade value of $2.2M across 3 products in 3 therapeutic categories. Based on 44 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Lupin Pharmaceutical Inc sources from 1 verified Indian supplier, with Lupin Limited accounting for 100.0% of imports.

Lupin Pharmaceutical Inc — Import Portfolio & Supplier Network

Lupin Pharmaceutical Inc import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Lupin Pharmaceutical Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$4.5M	107	100.0%

Lupin Pharmaceutical Inc sources from 1 verified Indian supplier across 65 distinct formulations. The sourcing is highly concentrated — Lupin Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Lupin Pharmaceutical Inc Import?

Formulation	Value	Ships
Sertraline TAB USP 100MG-500'sus.	$250.0K	5
Lisinopril TAB USP 5MG-1000'sus.	$226.1K	5
Lisinopril&hctz TAB USP 20/12.5MG-100's.	$153.0K	4
Sertraline TAB USP 50MG-500'sus.	$150.0K	3
Fenofibrate TAB USP 145MG 90s uncoat	$150.0K	3
Norethindrone tabs USP 0.35MG	$150.0K	3
Moxifloxacin opth soln0.53ML	$134.7K	6
Sertraline TAB USP 100MG-90'sus.	$128.9K	3
Sertraline TAB USP 100MG-5000'sus.	$100.0K	2
Lisinopril TAB USP 10MG-1000'sus r1.	$100.0K	2
Fenofibrate TAB USP 48MG 90 uncoat usa.	$100.0K	2
Lisinopril TAB USP 20MG-100'sus r1.	$100.0K	2
Lisinopril&hctz TAB USP 20/25MG-100's.	$100.0K	2
Divalproex sod er TAB 500MG x 500's us.	$100.0K	2
Lurasidone hcl tabs 80MG x 30's us.	$100.0K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lisinopril	Cardiovascular	$1.4M	28	2.3%	2
2	Sertraline	CNS & Psychiatric	$700.0K	14	0.1%	19
3	Darunavir	Antiviral & HIV Medications	$100.0K	2	0.2%	2

Lupin Pharmaceutical Inc imports 3 pharmaceutical products across 3 categories into United States totaling $2.2M.

Lupin Pharmaceutical Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Lupin Pharmaceutical Inc. is a U.S.-based pharmaceutical importer specializing in the acquisition and distribution of finished pharmaceutical formulations. Headquartered in Naples, Florida, the company operates as a subsidiary of Lupin Limited, a global pharmaceutical entity headquartered in Mumbai, India. Lupin Pharmaceutical Inc. plays a pivotal role in the U.S. pharmaceutical supply chain by sourcing a diverse array of generic medications from India, thereby enhancing the availability of affordable and high-quality drugs to the American market.

Established in 2003, Lupin Pharmaceutical Inc. has experienced significant growth, becoming one of the leading generic pharmaceutical companies in the United States. The company's portfolio encompasses a wide range of therapeutic categories, including cardiovascular, central nervous system (CNS) and psychiatric, and antiviral medications. By leveraging its strong relationships with Indian manufacturers, Lupin Pharmaceutical Inc. ensures a steady supply of essential medications, contributing to the overall health and well-being of the U.S. population.

2Distribution Network

Lupin Pharmaceutical Inc. maintains a robust distribution network across the United States, with key facilities located in Naples, Florida, and Bridgewater, New Jersey. The Naples location serves as the corporate headquarters, housing leadership and compliance teams overseeing operations in the Americas, including the U.S., Mexico, Brazil, and Canada. The Bridgewater facility accommodates various corporate functions, including commercial, human resources, finance, legal, marketing, business development, regulatory affairs, pharmacovigilance, and research and development. Additionally, the Somerset, New Jersey, site functions as Lupin's first and only commercial manufacturing facility in the U.S., encompassing all aspects of pharmaceutical manufacturing, including quality control, packaging, production, quality assurance, regulatory affairs, research and development, formulation, and technical services.

This strategic distribution network enables Lupin Pharmaceutical Inc. to efficiently manage its supply chain, ensuring timely delivery of pharmaceutical products to meet the demands of the U.S. market. The company's logistics capabilities are further enhanced by partnerships with global logistics providers, facilitating the swift movement of goods and maintaining the integrity of the supply chain.

3Industry Role

Lupin Pharmaceutical Inc. operates as a pharmaceutical importer and distributor within the United States, sourcing finished pharmaceutical formulations from Indian manufacturers and supplying them to various stakeholders in the U.S. healthcare system. The company's role is integral to the pharmaceutical supply chain, bridging the gap between Indian pharmaceutical manufacturers and the U.S. market. By importing a diverse range of generic medications, Lupin Pharmaceutical Inc. contributes to the availability of cost-effective treatment options for patients across the United States.

While Lupin Pharmaceutical Inc. does not function as a primary wholesaler, parallel importer, hospital supplier, or logistics intermediary, its operations are essential in ensuring the steady influx of generic medications into the U.S. market. The company's focus on importing finished pharmaceutical formulations allows it to maintain a specialized role, catering to the specific needs of the U.S. healthcare system and supporting the broader goal of providing accessible and affordable healthcare solutions.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Lupin Pharmaceutical Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Lupin Pharmaceutical Inc. demonstrates a high degree of sourcing concentration, importing finished pharmaceutical formulations exclusively from Lupin Limited, its parent company in India. This single-source dependency is both a strategic choice and a potential risk. On one hand, it allows for streamlined operations, consistent product quality, and favorable pricing due to the established relationship between the importer and the manufacturer. On the other hand, reliance on a single supplier exposes the company to risks associated with supply chain disruptions, such as production delays, regulatory issues, or geopolitical factors affecting trade between the U.S. and India.

The shipment data reveals a stable and consistent relationship between Lupin Pharmaceutical Inc. and Lupin Limited, with 44 shipments totaling $2.2 million in import value over the period from 2022 to 2026. The top three therapeutic categories imported—cardiovascular (63.6%), CNS & psychiatric (31.8%), and antiviral & HIV medications (4.5%)—indicate a focused product portfolio. However, the concentration of imports in a limited number of therapeutic areas may expose the company to market fluctuations within these segments.

2Supply Chain Resilience

The resilience of Lupin Pharmaceutical Inc.'s supply chain is closely tied to the stability and reliability of its sole supplier, Lupin Limited. While the exclusive sourcing arrangement ensures consistency in product quality and availability, it also means that any disruptions at Lupin Limited's manufacturing facilities could directly impact Lupin Pharmaceutical Inc.'s ability to meet U.S. market demands. The company has not publicly disclosed information regarding backup suppliers or alternative sourcing strategies, which suggests a potential vulnerability in its supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for the importation, distribution, and marketing of drugs within the U.S. This legislation mandates that all drugs imported into the United States must be safe, effective, and manufactured in compliance with FDA regulations.

The FDA's regulatory framework for pharmaceutical imports includes requirements for drug registration, labeling, and compliance with Good Manufacturing Practices (GMP). Imported drugs must meet FDA standards for quality, safety, and effectiveness, and are subject to inspection upon entry into the U.S. Drugs that are adulterated, misbranded, or unapproved may be refused entry.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. Importers must ensure that their products comply with FDA regulations, including obtaining necessary approvals and certifications. The FDA requires that all drugs imported into the U.S. meet its standards for quality, safety, and effectiveness.

Good Manufacturing Practices (GMP) certification is a critical component of the FDA's regulatory framework. The FDA recognizes GMP certifications from various international bodies, including the World Health Organization (WHO), the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and the European Union (EU). Manufacturers must adhere to these standards to ensure the quality and safety of their products.

Frequently Asked Questions — Lupin Pharmaceutical Inc

What products does Lupin Pharmaceutical Inc import from India?

Lupin Pharmaceutical Inc imports 3 pharmaceutical products across 3 categories. Top imports: Lisinopril ($1.4M), Sertraline ($700.0K), Darunavir ($100.0K).

Who supplies pharmaceuticals to Lupin Pharmaceutical Inc from India?

Lupin Pharmaceutical Inc sources from 1 verified Indian suppliers. The primary supplier is Lupin Limited (100.0% of imports, $4.5M).

What is Lupin Pharmaceutical Inc's total pharmaceutical import value?

Lupin Pharmaceutical Inc's total pharmaceutical import value from India is $2.2M, based on 44 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Lupin Pharmaceutical Inc focus on?

Lupin Pharmaceutical Inc imports across 3 categories. The largest: Cardiovascular (63.6%), CNS & Psychiatric (31.8%), Antiviral & HIV Medications (4.5%).

Get Full Lupin Pharmaceutical Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Lupin Pharmaceutical Inc

Lupin Pharmaceutical Inc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Lupin Pharmaceutical Inc?

What Formulations Does Lupin Pharmaceutical Inc Import?

What Products Does Lupin Pharmaceutical Inc Import?

Top Products by Import Value

Lupin Pharmaceutical Inc Therapeutic Categories — 3 Specializations